During the past decade, Tochigi Cancer Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Tochigi Cancer Center" are "Refractory Multiple Myeloma" (1 trials), "Relapsed Multiple Myeloma" (1 trials) and "Relapsed or Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "Tochigi Cancer Center" in a lesser frequency.

Most popular intervention types in "Tochigi Cancer Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carfilzomib" (2 trials), "Dexamethasone" (2 trials), "Daratumumab" (1 trials) and "Lenalidomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tochigi Cancer Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Tochigi Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tochigi Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tochigi Cancer Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Tochigi Cancer Center has several departments that took part in Clinical trials: "Tochigi Cancer Center" - 26 trials